Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Company Deals

QingSong Health and Basel Medical Forge Three-Year Strategic Alliance to Deploy AI-Driven Healthcare Solutions Across Southeast Asia

Fineline Cube Jun 11, 2026
Company Deals

WestGene Biopharma and Cartesian Therapeutics Forge $500M+ mRNA Partnership for In Vivo CAR-T and T Cell Engager Autoimmune Therapies

Fineline Cube Jun 10, 2026
Company Deals

Laekna Therapeutics Secures $527M Global Licensing Deal with Vasque Bio for PI3Kα Inhibitor LAE118, Retaining China Rights

Fineline Cube Jun 10, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma’s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal

Fineline Cube Jun 9, 2026
Company Drug Policy / Regulatory

PKU Hi-Tech Huatai Pharmaceuticals Blacklisted from China’s Volume-Based Procurement Following Quality Compliance Failures

Fineline Cube Jun 11, 2026
Company Drug

Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Fineline Cube Jun 11, 2026
Company Drug

Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML

Fineline Cube Jun 11, 2026
Company Deals

Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services

Fineline Cube Jun 27, 2022

China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm...

Medical Device

NMPA Approves Senscure’s Cryoablation Catheter and Kangduo’s Laparoscopic Surgery System

Fineline Cube Jun 27, 2022

The National Medical Products Administration (NMPA) has approved two innovative medical devices in China: Ningbo...

Company Deals

Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline

Fineline Cube Jun 27, 2022

Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...

Company Deals

PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform

Fineline Cube Jun 27, 2022

Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions”...

Company Drug

GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis

Fineline Cube Jun 27, 2022

UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...

Company Deals

Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies

Fineline Cube Jun 27, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot...

Drug

Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review

Fineline Cube Jun 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...

Company Deals

Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development

Fineline Cube Jun 24, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...

Company Drug

Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China

Fineline Cube Jun 24, 2022

The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co.,...

Company Deals

Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts

Fineline Cube Jun 24, 2022

China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off...

Company Drug

Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial

Fineline Cube Jun 24, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...

Company

Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China

Fineline Cube Jun 23, 2022

Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...

Company Drug

Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial

Fineline Cube Jun 23, 2022

China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...

Company Deals

Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development

Fineline Cube Jun 23, 2022

Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD...

Company Drug

Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors

Fineline Cube Jun 23, 2022

Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...

Company Drug

RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE

Fineline Cube Jun 23, 2022

China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...

Company Deals

Suzhou Teligene Ltd Plans IPO on Shanghai STAR Market for Cancer Drug Development

Fineline Cube Jun 23, 2022

China-based Suzhou Teligene Ltd has announced plans for an initial public offering (IPO) of 63.52...

Company Drug

BrightGene Bio-Medical Technology Gains NMPA Approval for Oseltamivir Dry Suspension

Fineline Cube Jun 23, 2022

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced receiving market approval from the...

Company Drug

Rakuten Medical Taiwan Administers First Dose of ASP-1929 in Phase II Trial

Fineline Cube Jun 22, 2022

Rakuten Medical Taiwan Inc. announced the administration of its photo-immunotherapy ASP-1929 to the first patient...

Company Drug

BeiGene’s Tislelizumab Accepted for Review in Gastric Cancer Treatment

Fineline Cube Jun 22, 2022

BeiGene (NASDAQ: BGNE) announced that a supplementary Biologic License Application (sBLA) for its programmed death-1...

Posts pagination

1 … 674 675 676 … 682

Recent updates

  • QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug
  • Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
  • Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML
  • CSPC Pharmaceutical’s Phase III Trial of Anbenitamab-Docetaxel Combination Meets Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer
  • Harbour BioMed’s IND for HBM7004 Bispecific Antibody Accepted by NMPA for Advanced Solid Tumors Following U.S. Clearance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Company Drug

Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Company Drug

Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML

Company Drug

CSPC Pharmaceutical’s Phase III Trial of Anbenitamab-Docetaxel Combination Meets Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.